[1]姜海燕.恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化对患者肝功能及血清HA、Ⅳ-C、PC-Ⅲ水平的影响[J].医学信息,2022,35(09):144-146.[doi:10.3969/j.issn.1006-1959.2022.09.036]
　JIANG Hai-yan.Effect of Entecavir Combined with Compound Glycyrrhizin on Liver Function and Serum Levels of HA, Ⅳ-C and PC-Ⅲ in Patients with Hepatitis B Cirrhosis[J].Medical Information,2022,35(09):144-146.[doi:10.3969/j.issn.1006-1959.2022.09.036]
点击复制

恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化对患者肝功能及血清HA、Ⅳ-C、PC-Ⅲ水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年09期
页码:
144-146
栏目:
论著
出版日期:
2022-05-01

文章信息/Info

Title:
Effect of Entecavir Combined with Compound Glycyrrhizin on Liver Function and Serum Levels of HA, Ⅳ-C and PC-Ⅲ in Patients with Hepatitis B Cirrhosis
文章编号:
1006-1959（2022）09-0144-03
作者:
姜海燕
（佳木斯市中心医院感染科，黑龙江 佳木斯 154002）
Author(s):
JIANG Hai-yan
(Department of Infection,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
恩替卡韦; 复方甘草酸苷; 乙型肝炎肝硬化; 肝功能
Keywords:
Entecavir; Compound glycyrrhizin; Hepatitis B cirrhosis; Liver function
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2022.09.036
文献标志码:
A
摘要:
目的 观察恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化临床疗效及其对患者肝功能及血清HA、Ⅳ-C、PC-Ⅲ水平的影响。方法 选取2020年5月-2021年1月我院诊治的78例乙型肝炎肝硬化患者为研究对象，采用随机数字表法分为对照组和观察组，各39例。对照组采用恩替卡韦治疗，观察组在对照组基础上联合复方甘草酸苷治疗，比较两组临床疗效、肝功能指标[总胆红素（TBIL）、天门冬氨酸酶（AST）、丙氨酸转氨酶（ALT）]、肝纤维化指标[血清透明质酸（HA）、IV型胶原（Ⅳ-C）、Ⅲ型前胶原（PC-Ⅲ）]以及不良反应发生情况。结果 观察组治疗总有效率为94.87%，高于对照组的82.05%（P＜0.05）；两组TBIL、AST、ALT均低于治疗前，且观察组低于对照组（P＜0.05）；两组HA、Ⅳ-C、PC-Ⅲ水平均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为5.13%，低于对照组的7.69%，但差异无统计学意义（P＞0.05）。结论 恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化效果较好，可提高治疗总有效率，改善肝功能，降低肝纤维化指标，且不良反应少，是一种安全有效的治疗方案。
Abstract:
Objective To observe the clinical efficacy of entecavir combined with compound glycyrrhizin in the treatment of hepatitis B cirrhosis and its influence on liver function and serum levels of HA, Ⅳ-C and PC-Ⅲ.Methods A total of 78 patients with hepatitis B cirrhosis who were treated in our hospital from May 2020 to January 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 39 cases in each group. The control group was treated with entecavir, and the observation group was treated with compound glycyrrhizin on the basis of the control group. The clinical efficacy, liver function indexes [total bilirubin (TBIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT)], liver fibrosis indexes [serum hyaluronic acid (HA), type Ⅳ collagen (Ⅳ-C), type Ⅲ procollagen (PC-Ⅲ)] and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 94.87%, which was higher than 82.05% of the control group (P<0.05). The levels of TBIL, AST and ALT in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). The levels of HA, Ⅳ-C and PC-Ⅲ in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). The incidence of adverse reactions in the observation group was 5.12%, which was lower than 7.69% in the control group, but the difference was not statistically significant (P>0.05).Conclusion Entecavir combined with compound glycyrrhizin is effective in the treatment of hepatitis B cirrhosis, which can improve the total effective rate, improve liver function, reduce liver fibrosis index, and has less adverse reactions. It is a safe and effective treatment plan.

参考文献/References:

[1]陈仕,周艳,耿颖.扶正化瘀胶囊联合恩替卡韦治疗乙型肝炎后肝硬化的疗效及对肝纤维化指标及免疫功能的影响[J].医学临床研究,2018,35(7):1385-1387. [2]赵云,朱培福.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能、HBV-DNA 和肝纤维化指标的影响[J].河北医药,2018,47(5):759-761. [3]郑岳,杨丽敏,王晋升.复方甘草酸苷联合恩替卡韦治疗乙肝患者早期肝硬化的临床研究[J].现代医学,2019,47(3):255-259.[4]王庆强,钱晶晶,左凌云,等.恩替卡韦治疗慢性乙型肝炎对机体炎症反应、肝功能及肝纤维化的影响[J].海南医学院学报,2018,24(14):22-25. [5]胡景岚.六味五灵片联合复方甘草酸苷治疗活动性慢性乙型肝炎肝硬化的疗效观察[J].现代药物与临床,2017,32(10):1908-1912. [6]高志荣,李青松,滕晓生.复方甘草酸苷片联合恩替卡韦治疗乙肝肝硬化患者的疗效观察[J].中国药物与临床,2019,19(9):104-106.[7]高晓红,郝晓芳,景鹏.不同核苷(酸) 类药物长期治疗对乙型肝炎肝硬化的影响[J].肝脏,2020,25(4):396-400．[8]李劲松,曾庆贵,钟俊.恩替卡韦对乙型肝炎肝硬化患者肝脏硬度的影响[J].西南国防医药,2018,28(1):67-68．[9]李丽萍,闻名,刘长明,等.恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎患者疗效及其对肝功能、肝纤维化和炎性反应的影响[J].疑难病杂志,2019,18(3):247-250. [10]刘艳.核苷类药物在乙型肝炎后肝硬化治疗中的疗效及对上消化道出血症状影响探析[J].现代消化及介入诊疗,2018,23(2):103．[11]那妍,娄宪芝.微生态制剂联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效[J].中国医科大学学报,2019,49(2):144-146.[12]孙振广,刘柯慧,曹竹君,等.恩替卡韦治疗核苷(酸)类初治或经治慢性乙型肝炎患者7年临床疗效分析[J].肝脏,2017,22(7):590-561．[13]徐京杭,李妮,陆海英,等.两种恩替卡韦片剂治疗慢性乙型肝炎患者的肝纤维化动态观察[J].北京医学,2014,36(12):999-1003．[14]韩开武.血清纤维化指标联合肝功能指标在肝硬化诊断中的应用[J].慢性病学杂志,2017,18(6):695-699．[15]杨年欢,袁国盛,周宇辰,等.恩替卡韦联合复方鳖甲饮肝片治疗慢性乙型肝炎肝纤维化96周的临床疗效[J].南方医科大学学报,2016,36(6):775-779.[16]吴芳,董乐妹,陈小微,等.化肝解毒汤联合复方甘草酸苷对慢性乙肝患者血清肝炎相关因子水平的影响[J].中国生化药物杂志,2017,37(5):131-133.[17]陈秀清.丹参注射液联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床研究[J].现代药物与临床,2016,31(6):878-881.[18]彭福江,张天晓,袁美蓉.复方甘草酸苷对慢性乙型肝炎患者肝功 能、肝纤维化指标及炎症因子的影响[J].海南医学院学报,2017,23(4):485-488． [19]李亚萍,张俊林.复方甘草酸苷治疗慢性重型乙型肝炎的疗效和安全性[J].新乡医学院学报,2016,33(1):45-47．

相似文献/References:

[1]唐平阳.恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的 临床疗效分析[J].医学信息,2018,31(10):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
　TANG Ping-yang.Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis[J].Medical Information,2018,31(09):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
[2]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,31(09):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[3]马 琳,田瑞民.乙型病毒性肝炎相关晚期肝病的抗病毒治疗效果观察[J].医学信息,2019,32(07):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
　MA Lin,TIAN Rui-min.Observation on the Effect of Antiviral Therapy For Advanced Hepatopathy Associated with Viral Hepatitis B[J].Medical Information,2019,32(09):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
[4]李嘉丽,温 静,周 甦,等.主动随访督导乙型肝炎肝硬化长期依从抗病毒的效果[J].医学信息,2019,32(10):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
　LI Jia-li,WEN Jing,ZHOU Su,et al.Active Follow-up to Monitor the Long-term Compliance with Antiviral Effects of Hepatitis B Cirrhosis[J].Medical Information,2019,32(09):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
[5]陈新华.拉米夫定联合恩替卡韦治疗乙型肝炎相关肝硬化的 长期疗效与安全性分析[J].医学信息,2019,32(18):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
　CHEN Xin-hua.Long-term Efficacy and Safety of Lamivudine Combined with Entecavir in the Treatment of Hepatitis B-related Cirrhosis[J].Medical Information,2019,32(09):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
[6]皮青文.恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响[J].医学信息,2022,35(15):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
　PI Qing-wen.Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis[J].Medical Information,2022,35(09):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
[7]周 煜.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响[J].医学信息,2019,32(22):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]
　ZHOU Yu.Effect of Entecavir Combined with Microecological Preparation on Liver Function and Prognosis in Patients with Hepatitis B Cirrhosis[J].Medical Information,2019,32(09):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]
[8]张 娜.不同种类核苷类似物治疗慢性乙型肝炎患者的疗效及对HBsAg水平的影响[J].医学信息,2021,34(09):96.[doi:10.3969/j.issn.1006-1959.2021.09.025]
　ZHANG Na.Efficacy of Different Kinds of Nucleoside Analogues in the Treatment of Patients with Chronic Hepatitis B and Their Influence on HBsAg Levels[J].Medical Information,2021,34(09):96.[doi:10.3969/j.issn.1006-1959.2021.09.025]
[9]张 瑜,路青华,曹海芳,等.聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响[J].医学信息,2021,34(17):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]
　ZHANG Yu,LU Qing-hua,CAO Hai-fang,et al.Effect of Polyethylene Glycol Interferon,PEG-IFN Combined with Entecavir on Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis B[J].Medical Information,2021,34(09):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]
[10]谭子跃.干扰素合并恩替卡韦治疗乙型病毒性肝炎患者的疗效及对患者肝功能的影响[J].医学信息,2023,36(20):137.[doi:10.3969/j.issn.1006-1959.2023.20.027]
　TAN Zi-yue.Effect of Interferon Combined with Entecavir in the Treatment of Patients with Hepatitis B and its Effect on Liver Function[J].Medical Information,2023,36(09):137.[doi:10.3969/j.issn.1006-1959.2023.20.027]

更新日期/Last Update: 1900-01-01